课题基金 / 基金详情

Development of clinical candidate hypoxia-activated DNA-PK inhibitors

Development of clinical candidate hypoxia-activated DNA-PK inhibitors
临床候选缺氧激活 DNA-PK 抑制剂的开发
批准号：
490356
负责人：
Minchinton Andrew I
金额：
$71.33万
依托单位：
B.C. Cancer Research Centre (Vancouver)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2023
资助国家：
加拿大
项目状态：
未结题
起止时间：
2023-09-01 至 2027-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=490356&lang=en
关键词：
Chemotherapy Clinical Drug Development Dna Damage Repair Inhibitors Dna-Pk Hypoxia Prodrug Prodrugs Radiotherapy Screening Cascade Tumour Microenvironment

项目摘要

项目成果

Minchinton Andrew I的其他基金

相似基金

相关文献

中文摘要
翻译
放疗和化疗仍然是治疗不能手术的癌症的主要方法。这些疗法会杀死癌细胞，但有些癌细胞由于其修复DNA损伤的能力而具有抗性。最近，可以阻断癌细胞生长的药物，
英文摘要
Radiation and chemotherapy remain the principal treatments for inoperable cancers. Cancer cells are killed following these therapies, but some are resistant due to their ability to repair the DNA damage. Recently, drugs that can block a cancer cell's abil
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FLASH radiotherapy - mechanisms and translational studies
Metabolic manipulation of hypoxia for improved radiotherapy response
Hypoxia-activated DNA repair inhibitors to improve cancer therapy
Hypoxia-selective inhibitors of DNA repair
海外基金